GENB vs UCFI
GENB: Generate Biomedicines is a clinical-stage biotechnology company leveraging generative artificial intelligence to design novel, programmable protein therapeutics. UCFI: An AI-powered health food technology company blending biotech innovation with traditional Chinese medicine to develop premium nutritional products for the Chinese market.
Side-by-side fundamentals
| Metric | GENB | UCFI | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $13.90 | $5.51 | |
| Market cap as of 2026-07-23 | $1.8B | $288M | |
| P/E as of 2026-07-23 | n/a | 66.26 | |
| Net margin as of 2026-07-23 | -637.0% | +30.3% | UCFI higher |
| Gross margin as of 2026-07-23 | n/a | +66.3% | |
| Operating margin as of 2026-07-23 | -737.0% | +42.4% | UCFI higher |
| ROE as of 2026-07-23 | -103.7% | +23.0% | UCFI higher |
| ROA as of 2026-07-23 | -61.5% | +8.1% | UCFI higher |
| Debt / equity as of 2026-07-23 | 0.01 | 0.18 | GENB lower |
| Beta as of 2026-07-23 | 0.52 | -0.38 | |
| 1-year return as of 2026-07-22 close | +13.8% | -48.5% | GENB higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.